ATRC News and Press, AtriCure Inc. From 04/08/21

AtriCure (ATRC) has named B. Kristine (Kris) Johnson as its new Board Chair. The current chair Scott Drake and another director Mark Lanning are not standing for reelection at the end of their terms in May 2021, the company said.A Board member at the company since 2017, Ms. Johnson sits ...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair. In addition, the Company announced that Scott Drake and Mark Lanning wi...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021. AtriCure will host a confer...

The following slide deck was published by AtriCure, Inc. in conjunction with this event. For further details see: AtriCure (ATRC)Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual Healthcare Conference. A...

Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q4 2020 Earnings Call Feb 23, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure Inc (ATRC) Q4 2020 Earnings Call Transcript

AtriCure, Inc. (ATRC) Q4 2020 Earnings Conference Call February 23, 2021 16:30 ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President & Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Mat...

AtriCure (ATRC): Q4 Non-GAAP EPS of -$0.18 beats by $0.07; GAAP EPS of -$0.42 misses by $0.13.Revenue of $57.73M (-5.9% Y/Y) misses by $0.23M.Shares -5.03%.Press Release For further details see: AtriCure EPS beats by $0.07, misses on revenue

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results. “Despite challenges posed in 2020 as a result of the...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10 th Annual Global Healthcare Conference...